Complement inhibitors are useful in secondary hemolytic uremic syndromes

The term hemolytic uremic syndrome (HUS) encompasses 3 different entities: typical HUS caused by a shiga toxin –producing Escherichia coli, primary atypical HUS (aHUS) resulting from the dysregulation of the complement alternative pathway, and secondary HUS caused by a variety of etiologies whose common characteristic is to induce diffuse endothelial damage leading to thrombotic microangiopathy (TMA). As s hown in Supplementary Table S1, the most common causes of secondary HUS are drugs, infections, autoimmune diseases, malignancies, and hematopoietic stem cell transplantation.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Controversies in Nephrology Source Type: research